A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
NCT06532032
Bronchial Neoplasms, Carcinoma, Bronchogenic
Irvine, California, United States
View Trial DetailsNCT Number: NCT00973427
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).
Looking for future studies?
Notify Me18 year–75 year
All sexes
Observational
Aarhus University Hospital, Aarhus, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 5 years
Time frame: 5 years
Medical Prognosis Institute A/S
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06532032
Bronchial Neoplasms, Carcinoma, Bronchogenic
Irvine, California, United States
View Trial DetailsNCT04776447
Bronchial Neoplasms, Carcinoma Bronchiogenic Stage III
Alicante, Spain
View Trial DetailsNCT04592523
Anaplastic Lymphoma Kinase, Bronchial Neoplasms
Busan, South Korea
View Trial DetailsNCT06678555
Bronchial Neoplasms, Carcinoma, Bronchogenic
Taipei, Taiwan
View Trial Details